opiod system
Spotlight: Antidepressants and the endogenous opioid system (Fricker, et al, 2025)
"A growing body of evidence links the opioid system w/ major depressive disorder... two different widely used antidepressants, tianeptine & ketamine, both interact with MOR; tianeptine as a full agonist, ketamine as a positive allosteric modulator. Both produce antidepressant effects within days."
ketamine
Spotlight: Synaptic priming: A framework for pharmacotherapy in depression (Brown, et al, 2025)
"we describe how the indirect relationship between ketamine's pharmacokinetics and sustained antidepressant pharmacodynamics reveals a dosing model (primer pharmacology) that can be harnessed to fine-tune therapeutic outcomes."
ketamine
Ketamine Sustains and Enhances the Protective Effects of a Ketogenic Diet Against Relapses in an Anorexia Mouse Model (Dong, et al, 2025)
"Ketamine sustains and boosts Ketogenic Diet benefits for > 10 days, supporting clinical findings that short-term KGD + KET may be an effective treatment for preventing anorexia nervosa relapses."
cognitive behavioral therapy
Change in the Neural Response to Auditory Deviance Following Cognitive Therapy for Hallucinations in Patients With Schizophrenia (Knott, et al, 2020)
"These findings of improved auditory information processing and symptom-response attributable to CBTv suggest potential clinical and functional benefits of psychotherapeutical approaches for patients with persistent AVHs."
at home ketamine
Spotlight: Ketamine Harm Reduction
Prevention & Treatment in Ketamine Use Disorder - When a medicine becomes a poison
oxycodone withdrawal
Spotlight: The effects of low-dose ketamine and (2R,6R)-Hydroxynorketamine on affective behaviors associated with protracted oxycodone withdrawal (Lehane, et al, 2025)
"These findings demonstrate the therapeutic potential of (2R,6R)-HNK and ketamine in alleviating affective symptoms of oxycodone withdrawal. "
ketamine
Naltrexone in the Treatment of Ketamine Use Disorders: A Case Report and Literature Review (Verma, et al, 2025)
"findings consistent w/ 2 prior reports - use of naltrexone in KUDs at the dosage of 50 mg/day successfully helped patients achieve abstinence... naltrexone reduces antidepressant effects of ketamine, indicating overlap between opioid system & ketamine's NMDA receptor activity. "
ketamine
Spotlight: Ketamine for treatment-resistant post-traumatic stress disorder: double-blind active-controlled randomised crossover study (Beaglehole, et al, 2025)
"We provide preliminary support for the efficacy and tolerability of i.m. ketamine in a community sample of individuals with PTSD."
ketamine
Spotlight: The transformational power of psychedelics: catalysts for creativity, consciousness, and mental health (Du, et al, 2025)
"Psychedelics, such as psilocybin, lysergic acid diethylamide (LSD), ketamine, and N,N-dimethyltryptamine (DMT), have captured the attention of scientists, artists, and seekers alike for their profound ability to alter consciousness and inspire creativity."
iv ketamine
Spotlight: Efficacy of Intravenous Racemic Ketamine on Global Severity and Individual Symptoms of Depression: An Exploratory Retrospective Analysis (Landrum, et al, 2025)
" Maintenance intravenous racemic ketamine therapy demonstrated significant, persistent, and broad efficacy for treatment-resistant depression ...Side effect burden was no greater in higher doses as compared with lower. "
ketamine
Spotlight: Ketamine's Role in Neuroinflammation and Neuroprotection Across Neurological and Psychiatric Disorders: A Narrative Review (Silva, et al, 2025)
"Our findings indicate that ketamine reduces excitotoxicity and inflammation, which may contribute to neuroprotection in acute neurological injuries. These insights underscore ketamine's potential as an adjunctive neuroprotective agent, warranting further clinical investigation...
ketamine
Characteristics of Ongoing Clinical Trials of Psychogenic Substances for Psychiatric Disorders (Havlik, et al, 2025)
"The most frequently studied substances were psilocybin (n=64; 35.4%) and ketamine (n=61; 33.7%). Trials were notably concentrated within a small number of leading academic institutions."
ketamine
Evaluating oral ketamine's adverse side effects in chronic pain patients (Hom, et al, 2025)
Evaluating oral ketamine’s adverse side effects in chronic pain patients - PubMedOur results suggest that at daily doses above
ketamine
Spotlight: Comparative Effects of Repeated Ketamine Infusion Versus Intranasal Esketamine in Patients With Treatment-Resistant Depression: A Retrospective Chart Review (Meisner, et al, 2025)
"In this naturalistic sample of patients with similarly severe TRD treated in a ketamine subspecialty service over a 4–5-week induction period, treatment with IV racemic ketamine was associated with a more rapid response and greater overall efficacy than treatment with IN esketamine."
ketamine
Spotlight: Ketamine's Therapeutic Role in Substance Use Disorders: A Narrative Review (Thomas, et al, 2025)
"...ketamine has been tested in nine RBCTs targeting cocaine, alcohol, opioid use disorder, and nicotine, suggesting efficacy for addiction in combination with psychotherapies, and often when doses produce subjectively reported mystical or psychedelic experiences."
ketamine
Ketamine/esketamine in the treatment of depression with comorbid borderline personality disorder or traits: A systematic review of effectiveness (Scott, et al, 2025)
"patients with depression and comorbid borderline personality disorder/traits were equally likely to respond to ketamine/esketamine as those with depression but without borderline personality disorder/traits."
ketamine
Exploring the Therapeutic Potential of Ketamine and Psilocybin in Comparison to Current Treatment Regimens for Treatment-Resistant Depression, Mood Disorders, and Post-traumatic Stress Disorder in the Pediatric Population (Hughes, et al, 2025)
"Ketamine's use for pediatric TRD demonstrated rapid-onset relief for signs and symptoms of depression in children and adolescents, and psilocybin also decreased symptoms in patients with longstanding or refractory depression. Ketamine has been well tolerated and exhibited symptom improvements"
ketamine
Psychedelics and mental health: reimagining care through science, insight, and compassion (Mikellides, et al, 2025)
"These substances are not stand-alone medications; rather, they function as adjuncts to intensive psychotherapeutic processes. Training therapists and establishing ethical, evidence-based protocols is essential."
